ReviewTrends in microbiology2013
Decoding the complexity of type I interferon to treat persistent viral infections.
Review in Trends in microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Functional Type I and Type II interferon crosstalk restricts progenitor exhausted CD8 T cells through spatial exclusion and checkpoint enforcement.bioRxiv : the preprint server for biology · 2026Article
- SARS CoV-2 infection as a risk factor of preeclampsia and pre-term birth. An interplay between viral infection, pregnancy-specific immune shift and endothelial dysfunction may lead to negative pregnancy outcomes.Annals of medicine · 2023Review
- Article
- Deletion of immune evasion genes provides an effective vaccine design for tumor-associated herpesviruses.NPJ vaccines · 2020Article
- LncRNAs in the Type I Interferon Antiviral Response.International journal of molecular sciences · 2020Review
- USP18 is a significant driver of memory CD4 T-cell reduced viability caused by type I IFN signaling during primary HIV-1 infection.PLoS pathogens · 2019Article
- Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication.PLoS pathogens · 2018Article
- Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for Protective Immunity.Viruses · 2017Review
- The unique immunological and microbial aspects of pregnancy.Nature reviews. Immunology · 2017Article
- Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement.Nature communications · 2017Article
- Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.The Journal of clinical investigation · 2017Article
- Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.AIDS research and human retroviruses · 2016Article
- Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-α Production in Women.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Bacterial expression and preliminary crystallographic studies of a 149-residue fragment of human Caprin-1.Acta crystallographica. Section F, Structural biology communications · 2015Article
- Human pDCs preferentially sense enveloped hepatitis A virions.The Journal of clinical investigation · 2015Article
- Epigenetic manipulation restores functions of defective CD8⁺ T cells from chronic viral infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis.Trends in parasitology · 2014Review
- The role of type I interferons in intestinal infection, homeostasis, and inflammation.Immunological reviews · 2014Review
- Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- The bacterial pathogen Listeria monocytogenes and the interferon family: type I, type II and type III interferons.Frontiers in cellular and infection microbiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type I interferons (IFN-I) are a broad family of cytokines that are central to the innate immune response. These proteins have long been appreciated for the critical roles they play in restraining viral infections and shaping antiviral immune responses. However, in recent years there has been increased awareness of the immunosuppressive actions of these proteins as well. Although there are many current therapeutic applications to manipulate IFN-I pathways, we have limited understanding of the mechanisms by which these therapies are actually functioning. In this review, we highlight the diversity and temporal impact of IFN-I signaling, discuss the current therapeutic uses of IFN-I, and explore the strategy of blocking IFN-I to alleviate immune dysfunction in persistent virus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.